1. Home
  2. EMPD vs TENX Comparison

EMPD vs TENX Comparison

Compare EMPD & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Empery Digital Inc.

EMPD

Empery Digital Inc.

N/A

Current Price

$2.88

Market Cap

88.4M

Sector

N/A

ML Signal

N/A

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

N/A

Current Price

$1.65

Market Cap

74.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EMPD
TENX
Founded
2020
1967
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
88.4M
74.1M
IPO Year
2021
2001

Fundamental Metrics

Financial Performance
Metric
EMPD
TENX
Price
$2.88
$1.65
Analyst Decision
Buy
Analyst Count
0
10
Target Price
N/A
★ $12.56
AVG Volume (30 Days)
113.4K
★ 2.2M
Earning Date
11-09-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 94.47
N/A
EPS
N/A
★ N/A
Revenue
★ $974,977.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$2.48
$1.31
52 Week High
$7.35
$19.40

Technical Indicators

Market Signals
Indicator
EMPD
TENX
Relative Strength Index (RSI) 45.08 36.29
Support Level $2.78 $1.31
Resistance Level $3.29 $2.00
Average True Range (ATR) 0.18 0.10
MACD -0.03 0.08
Stochastic Oscillator 37.33 46.09

Price Performance

Historical Comparison
EMPD
TENX

About EMPD Empery Digital Inc.

Empery Digital Inc is an all-electric, off-road powersports vehicle company developing and building electric two and four-wheel motorcycles and utility terrain vehicles, also known as side-by-sides, along with a complete line of upgrades and accessories. The company's products include motorcycle and UTV products that are all-electric and designed for off-road use.

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

Share on Social Networks: